Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome: Data from an expanded access program
Open Access
- 4 November 2025
- journal article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (1) , 104-111
Abstract
No abstract availableKeywords
Funding Information
- Chiesi Farmaceutici
- Università degli Studi di Palermo
- Aegerion Pharmaceuticals
This publication has 21 references indexed in Scilit:
- Real-world safety and effectiveness of lomitapide in homozygous familial hypercholesterolaemia over ten years: Data from the lomitapide observational worldwide evaluation registry (LOWER)Atherosclerosis, 2025
- Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive CardiologyAmerican Journal of Preventive Cardiology, 2025
- Efficacy and safety of lomitapide in familial chylomicronaemia syndromeAtherosclerosis, 2022
- Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)Current Atherosclerosis Reports, 2021
- Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemiaAtherosclerosis, 2019
- Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life spanJournal of Clinical Lipidology, 2018
- Severe Hypertriglyceridemia With PancreatitisJAMA Internal Medicine, 2014
- Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistatJournal of Clinical Lipidology, 2013
- The NAFLD fibrosis scoreHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006